Menard H A, Mathieu J P, de Medicis R, Lussier A
J Rheumatol. 1979 Mar-Apr;6(2):156-62.
The therapeutic value of sodium aurothiomalate, D-penicillamine and levamisole was evaluated in three comparable groups of 20 rheumatoid arthritis (RA) patients. There was no intergroup difference after a 3-month follow-up and all were significantly improved (p less than 0.001). To verify if, in these patients, the presence of antinuclear antibodies (ANA) had influenced the therapeutic results, each group was retrospectively subdivided according to the ANA status. To start with, all the sub-groups were statistically comparable on the basis of measures of disease activity. The D-penicillamine group could not be analyzed. In the gold treated group, the ANA negative patients were more improved than the ANA positive (p = 0.03), and very significantly more than the levamisole-treated ANA-negative patients (p = 0.005). The ANA negative patients taking levamisole had less pain relief (p = 0.01) and showed a tendency for less overall improvement (p = 0.15) than the ANA positive patients. This preliminary study supports the idea that systematic ANA testing in RA may be of practical and theoretical value.
对三组各20例类风湿性关节炎（RA）患者评估了硫代苹果酸金钠、D-青霉胺和左旋咪唑的治疗价值。经过3个月的随访，组间无差异，且所有患者均有显著改善（p<0.001）。为验证在这些患者中抗核抗体（ANA）的存在是否影响治疗结果，根据ANA状态对每组进行回顾性细分。首先，所有亚组在疾病活动度测量基础上具有统计学可比性。D-青霉胺组无法进行分析。在金制剂治疗组中，ANA阴性患者比ANA阳性患者改善更明显（p = 0.03），且比左旋咪唑治疗的ANA阴性患者改善非常显著（p = 0.005）。服用左旋咪唑的ANA阴性患者与ANA阳性患者相比，疼痛缓解程度更低（p = 0.01），且总体改善趋势较小（p = 0.15）。这项初步研究支持了在类风湿性关节炎中进行系统性ANA检测可能具有实践和理论价值这一观点。
